EGFR and neoplasm: Cetuximab, an EGFR monoclonal antibody, binds to its ligand to block the activation of the RAS/RAF/MAPK pathway, inhibiting tumor growth.[28, 29] The NCCN, CSCO, and EMSO guidelines recommend cetuximab as a first‐line treatment for RAS wild‐type metastatic CRC.